I don't think the short exit is mainly going to do it... not often a billion dollar startup has a binary yes will be successful or not outcome. I think the buying pressure from everyone else will far outweigh the shorts. Not many other.. infact no other biotech on ASX with the phase 3 opportunity pool msb has.
Remember as Reg says, first cab off the ramp will be expansion into adult trial, which is a 6 - 9x market value than pediatric.
Concurrently the CLBP has over 1,000 times the number of patients alone, than pediatric sr gvhd, and MSB have been busy updating their bioreactor , bovine free serum patents. The yields are better than with FBS according to the patent.
Approval means rapid pathway to greatness.
I don't think the short exit is mainly going to do it... not...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
-0.005(0.51%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| 98.5¢ | 98.5¢ | 96.0¢ | $2.168M | 2.226M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16000 | 96.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.0¢ | 86854 | 7 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |